{"id":"rt-plus-nimotuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Radiation dermatitis"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dysphagia"}]},"_chembl":{"chemblId":"CHEMBL2108359","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream proliferation signals. When combined with radiotherapy, it enhances radiosensitivity and reduces tumor cell survival. This combination approach targets both the growth factor signaling pathway and DNA damage response mechanisms.","oneSentence":"Nimotuzumab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling, combined with radiotherapy (RT) to enhance tumor cell death in cancer treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:56.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck cancer (in combination with radiotherapy)"},{"name":"Nasopharyngeal carcinoma (in combination with radiotherapy)"}]},"trialDetails":[{"nctId":"NCT04456322","phase":"PHASE3","title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-17","conditions":"Nasopharyngeal Carcinoma","enrollment":381},{"nctId":"NCT00957086","phase":"PHASE3","title":"Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2009-08-13","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":710},{"nctId":"NCT03620032","phase":"PHASE2","title":"Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2015-11-02","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":54},{"nctId":"NCT00702481","phase":"PHASE2","title":"Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2008-04-28","conditions":"Head and Neck Cancer","enrollment":32},{"nctId":"NCT03837808","phase":"PHASE3","title":"Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-04-11","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases","enrollment":384},{"nctId":"NCT02577341","phase":"PHASE2","title":"Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small-cell Lung Cancer","enrollment":122},{"nctId":"NCT03388372","phase":"PHASE2","title":"Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2010-08-18","conditions":"Glioblastoma","enrollment":39},{"nctId":"NCT02409186","phase":"PHASE3","title":"A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2015-03","conditions":"Prosthesis Survival","enrollment":200},{"nctId":"NCT00753246","phase":"PHASE3","title":"Nimotuzumab in Adults With Glioblastoma Multiforma","status":"COMPLETED","sponsor":"Oncoscience AG","startDate":"2007-08","conditions":"Adults With Glioblastoma Multiforma","enrollment":150},{"nctId":"NCT01516996","phase":"PHASE2","title":"Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer","status":"UNKNOWN","sponsor":"The Second People's Hospital of Sichuan","startDate":"2012-03","conditions":"Oropharyngeal Cancer, Hypopharyngeal Cancer","enrollment":80},{"nctId":"NCT01393184","phase":"PHASE2","title":"Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-03","conditions":"SCCHN","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RT plus Nimotuzumab","genericName":"RT plus Nimotuzumab","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimotuzumab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling, combined with radiotherapy (RT) to enhance tumor cell death in cancer treatment. Used for Head and neck cancer (in combination with radiotherapy), Nasopharyngeal carcinoma (in combination with radiotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}